Please login to the form below

Not currently logged in
Email:
Password:

Crescendo Biologics appoints Peter Pack as CEO

Launches new strategy in oncology R&D
Crescendo Peter Pack

Crescendo Biologics has appointed Dr Peter Pack as CEO who will help to oversee the company's new strategy.

Crescendo is now shifting its focus to oncology with novel VH-based checkpoint modulators and humabody drug conjugate (HDC) therapeutics.

Dr Pack joins with over 23 years of corporate experience in the life science industry. He has also previously served on the board of Signature Diagnostics AG before its sale to Roche in February 2015. 

His appointment is representative of Crescendo expanding its oncology pipeline by targeting a range of cancer indications where humabodies have the potential to deliver high-value treatments to patients where there is an unmet medical need.

He said: “The transition to a product-oriented oncology therapeutics company is a pivotal moment in Crescendo's corporate development. In my view Crescendo's in vivo maturation technology for 100% human VHs with excellent affinities, expression yields and plug and play options is superior to anything that has been done before.

“We plan to advance the development of new and innovative therapeutics compounds in the area of oncology including immune-oncology, the new primary focus of the work at Crescendo. We intend to expand rapidly our internal oncology programmes on checkpoint modulators and HDCs, which are a novel alternative to antibody drug conjugates.”

20th October 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Improve clinical trials through patient journey mapping
Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...

Infographics